TY  - JOUR
AU  - Jahn, Nikolaus
AU  - Jahn, Ekaterina
AU  - Saadati, Maral
AU  - Bullinger, Lars
AU  - Larson, Richard A
AU  - Ottone, Tiziana
AU  - Amadori, Sergio
AU  - Prior, Thomas W
AU  - Brandwein, Joseph M
AU  - Appelbaum, Frederick R
AU  - Medeiros, Bruno C
AU  - Tallman, Martin S
AU  - Ehninger, Gerhard
AU  - Heuser, Michael
AU  - Ganser, Arnold
AU  - Pallaud, Celine
AU  - Gathmann, Insa
AU  - Krzykalla, Julia
AU  - Benner, Axel
AU  - Bloomfield, Clara D
AU  - Thiede, Christian
AU  - Stone, Richard M
AU  - Döhner, Hartmut
AU  - Döhner, Konstanze
TI  - Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
JO  - Leukemia
VL  - 36
IS  - 9
SN  - 0887-6924
CY  - London
PB  - Springer Nature
M1  - DKFZ-2022-01731
SP  - 2218-2227
PY  - 2022
N1  - 2022 Sep;36(9):2218-2227
AB  - The aim of this study was to characterize the mutational landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the randomized CALGB 10603/RATIFY trial evaluating intensive chemotherapy plus the multi-kinase inhibitor midostaurin versus placebo. We performed sequencing of 262 genes in 475 patients: mutations occurring concurrently with the FLT3-mutation were most frequent in NPM1 (61
LB  - PUB:(DE-HGF)16
C6  - pmid:35922444
DO  - DOI:10.1038/s41375-022-01650-w
UR  - https://inrepo02.dkfz.de/record/181024
ER  -